Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 4, 2011, Pages 763-772

  Ruan, Xiangbo ^a   Li, Zhenghu ^a   Zhang, Yixuan ^a   Yang, Ling ^a   Pan, Yi ^a   Wang, Zhenzhen ^a   Feng, Gen Sheng ^b   Chen, Yan ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein A I (ApoA I); Brown fat; Energy expenditure; Obesity

Indexed keywords

AMP ACTIVATED PROTEIN KINASE KINASE; AMP-ACTIVATED PROTEIN KINASE KINASE; ANTIOBESITY AGENT; APOLIPOPROTEIN A1; D 4F PEPTIDE; D-4F PEPTIDE; INSULIN; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN; PROTEIN KINASE;

ADIPOCYTE; ANIMAL; ARTICLE; BROWN ADIPOSE TISSUE; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; ENERGY METABOLISM; ENZYMOLOGY; FAT INTAKE; FEEDING BEHAVIOR; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; OBESITY; PHOSPHORYLATION; TRANSGENIC MOUSE; UPREGULATION;

ADIPOCYTES; ADIPOSE TISSUE, BROWN; ADIPOSITY; ANIMALS; ANTI-OBESITY AGENTS; APOLIPOPROTEIN A-I; CELLS, CULTURED; DIETARY FATS; ENERGY METABOLISM; FEEDING BEHAVIOR; HUMANS; INSULIN; ION CHANNELS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIAL PROTEINS; OBESITY; PHOSPHORYLATION; PROTEIN KINASES; UP-REGULATION;

MUS; MUS MUSCULUS;

EID: 79955666194     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01045.x     Document Type: Article

References (42)

1. James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil. 2004; 11: 3-8.
2. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005; 56: 45-62.
3. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997; 46: 3-10.
4. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000; 106: 453-8.
5. Must A, Spadano J, Coakley EH, et al The disease burden associated with overweight and obesity. Jama. 1999; 282: 1523-9.
6. Kenchaiah S, Evans JC, Levy D, et al Obesity and the risk of heart failure. N Engl J Med. 2002; 347: 305-13.
7. Lakka TA, Lakka HM, Salonen R, et al Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis. 2001; 154: 497-504.
8. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-80.
9. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 2003; 54: 321-41.
10. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005; 4: 193-205.
11. Maciejko JJ, Holmes DR, Kottke BA, et al Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983; 309: 385-9.
12. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity. 2007; 15: 2875-88.
13. Garrison RJ, Wilson PW, Castelli WP, et al Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism. 1980; 29: 1053-60.
14. Vajo Z, Terry JG, Brinton EA. Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women. Atherosclerosis. 2002; 160: 495-501.
15. Chen ES, Mazzotti DR, Furuya TK, et al Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med. 2009; 9: 319-25.
16. Han R, Lai R, Ding Q, et al Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia. 2007; 50: 1960-8.
17. Navab M, Anantharamaiah GM, Reddy ST, et al Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005; 25: 1325-31.
18. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep. 2009; 11: 52-7.
19. Navab M, Hama SY, Anantharamaiah GM, et al Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000; 41: 1495-508.
20. Troutt JS, Alborn WE, Mosior MK, et al An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma. J Lipid Res. 2008; 49: 581-7.
21. Peterson SJ, Husney D, Kruger AL, et al Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther. 2007; 322: 514-20.
22. Weihrauch D, Xu H, Shi Y, et al Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol. 2007; 293: H1432-41.
23. Buga GM, Frank JS, Mottino GA, et al D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J Lipid Res. 2008; 49: 192-205.
24. Charles-Schoeman C, Banquerigo ML, Hama S, et al Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol. 2008; 127: 234-44.
25. Bloedon LT, Dunbar R, Duffy D, et al Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008; 49: 1344-52.
26. Navab M, Anantharamaiah GM, Hama S, et al Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002; 105: 290-2.
27. Rubin EM, Ishida BY, Clift SM, et al Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA. 1991; 88: 434-8.
28. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. 1949; 109: 1-9.
29. Bronnikov G, Houstek J, Nedergaard J. Beta-adrenergic, cAMP-mediated stimulation of proliferation of brown fat cells in primary culture. Mediation via beta 1 but not via beta 3 adrenoceptors. J Biol Chem. 1992; 267: 2006-13.
30. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444: 840-6.
31. Ricquier D. Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc. 2005; 64: 47-52.
32. Seale P, Kajimura S, Yang W, et al Transcriptional control of brown fat determination by PRDM16. Cell Metab. 2007; 6: 38-54.
33. Wu Z, Puigserver P, Andersson U, et al Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999; 98: 115-24.
34. Drew BG, Fidge NH, Gallon-Beaumier G, et al High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA. 2004; 101: 6999-7004.
35. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004; 84: 277-359.
36. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009; 360: 1500-8.
37. Virtanen KA, Lidell ME, Orava J, et al Functional brown adipose tissue in healthy adults. N Engl J Med. 2009; 360: 1518-25.
38. Cypess AM, Lehman S, Williams G, et al Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009; 360: 1509-17.
39. Anantharamaiah GM. Synthetic peptide analogs of apolipoproteins. Methods Enzymol. 1986; 128: 627-47.
40. Peterson SJ, Drummond G, Kim DH, et al L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res. 2008; 49: 1658-69.
41. Villena JA, Viollet B, Andreelli F, et al Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-alpha2 subunit. Diabetes. 2004; 53: 2242-9.
42. Narkar VA, Downes M, Yu RT, et al AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008; 134: 405-15.